financetom
Business
financetom
/
Business
/
Nike Poised for Quarterly Earnings Beat, Guide Third-Quarter Below Street, Morgan Stanley Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nike Poised for Quarterly Earnings Beat, Guide Third-Quarter Below Street, Morgan Stanley Says
Dec 13, 2024 12:52 PM

03:36 PM EST, 12/13/2024 (MT Newswires) -- Nike ( NKE ) is expected to deliver a fiscal second-quarter earnings beat, but guide the third quarter below Wall Street's expectations amid potential downside to sales and gross margin, Morgan Stanley said in a note emailed Friday.

The athletic footwear and apparel maker is scheduled to release second-quarter results Thursday. Morgan Stanley projects earnings at $0.67 a share, which it said would top the Street's $0.65 view, mainly due to selling, general, and administrative expense discipline.

The brokerage sees sales falling 10% year over year versus the Street's call for a 9% decline and Nike's ( NKE ) own outlook range indicating an 8% to 10% drop. Almost all company data points during the period were "incrementally negative," leading to Morgan Stanley's below-consensus sales view, the brokerage said.

The firm expects Nike ( NKE ) to guide third-quarter EPS between $0.55 and $0.60, and sales dropping by high-single-digit to low-double-digit percentage, lagging the Street's projections for $0.65 and a 7% decline, respectively. The brokerage expects "inventory digestion" and sales and promotion pressures to linger in the near term.

Morgan Stanley reduced its price target on the Nike ( NKE ) stock to $80 from $82 while maintaining its equal-weight rating. The company's shares were down 0.8% in Friday late-afternoon trade. The stock has shed 29% in value so far this year.

In September, Nike ( NKE ) said that Elliott Hill would become its chief executive. In October, the company withdrew its full-year guidance given the CEO transition.

Nike ( NKE ) is unlikely to reinstate the outlook amid factors such as Hill's short tenure so far and a lack of clarity around the company's strategy, Morgan Stanley said. The brokerage added that it's doubtful of Nike ( NKE ) and the Street's assumptions that fundamentals could "meaningfully improve" in the second half of the year.

Morgan Stanley cut its full-year EPS outlook to $2.45 from $2.60 and now sees sales decreasing 9% versus its prior projection calling for an 8% decline.

"Altogether, while (Nike's ( NKE )) go-forward strategy is outstanding, (and) there's little evidence of turnaround in the fundamentals, but it also enjoys a new-CEO halo, we think the stock proves mostly range-bound," the brokerage wrote.

Price: 77.32, Change: -0.64, Percent Change: -0.83

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Coinbase Global Insider Sold Shares Worth $2,186,640, According to a Recent SEC Filing
Coinbase Global Insider Sold Shares Worth $2,186,640, According to a Recent SEC Filing
Nov 27, 2024
04:17 PM EST, 11/27/2024 (MT Newswires) -- Paul Grewal, Chief Legal Officer, on November 25, 2024, sold 7,104 shares in Coinbase Global ( COIN ) for $2,186,640. Following the Form 4 filing with the SEC, Grewal has control over a total of 79,407 shares of the company, with 79,407 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1679788/000167978824000211/xslF345X05/wk-form4_1732742035.xml ...
Eastman Chemical Insider Sold Shares Worth $471,623, According to a Recent SEC Filing
Eastman Chemical Insider Sold Shares Worth $471,623, According to a Recent SEC Filing
Nov 27, 2024
04:13 PM EST, 11/27/2024 (MT Newswires) -- Julie A. McAlindon, Senior Vice President, Regions, and Chief Supply Chain Officer, on November 26, 2024, sold 4,456 shares in Eastman Chemical ( EMN ) for $471,623. Following the Form 4 filing with the SEC, McAlindon has control over a total of 5,240 shares of the company, with 4,403 shares held directly and...
US FDA declines to approve Applied Therapeutics' genetic disease drug
US FDA declines to approve Applied Therapeutics' genetic disease drug
Nov 27, 2024
Nov 27 (Reuters) - The U.S. Food and Drug Administration on Wednesday declined to approve Applied Therapeutics' ( APLT ) drug to treat galactosemia, a rare genetic metabolic disease, the company said. ...
Mexican retailer Elektra to propose going private
Mexican retailer Elektra to propose going private
Nov 27, 2024
MEXICO CITY, Nov 27 (Reuters) - Mexican retailer Grupo Elektra on Wednesday called a shareholders' meeting in which it will propose privatizing the company, which would make it the latest to exit Mexico's main stock exchange. Elektra added in a filing that 95% of its shareholders have expressed interest in taking the firm private. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved